The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking
Open accessThe DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Abstract
Emerging evidence suggests that FcγR-mediated cross-linking of tumor-bound mAbs may induce signaling in tumor cells that contributes to their therapeutic activity. In this study, we show that daratumumab (DARA), a therapeutic human CD38 mAb with a broad-spectrum killing activity, is able to induce programmed cell death (PCD) of CD38+ multiple myeloma tumor cell lines when cross-linked in vitro by secondary Abs or via an FcγR. By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRγ-chain knockout or NOTAM mice carrying a signaling-inactive FcRγ-chain, we found that the inhibitory FcγRIIb as well as activating FcγRs induce DARA cross-linking–mediated PCD. In conclusion, our in vitro and in vivo data show that FcγR-mediated cross-linking of DARA induces PCD of CD38-expressing multiple myeloma tumor cells, which potentially contributes to the depth of response observed in DARA-treated patients and the drug’s multifaceted mechanisms of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Jiang, H., Acharya, C., An, G., Zhong, M., Feng, X., Wang, L., Dasilva, N., Song, Z., Yang, G., Adrian, F., et al. (2016) · Leukemia · doi:10.1038/leu.2015.240 · Cited by 219 · cited 1×
“The homotypic aggregation–related caspase-independent and -dependent PCD was also shown for SAR650984, a chimeric CD38 Ab (40, 41), in the absence of secondary cross-linking.”
BackgroundRetractedKyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssière, J. L., Petit, P. X., & Kroemer, G. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1661 · Cited by 1,166
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
Methodde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationMössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
FcR γ chain deletion results in pleiotrophic effector cell defects
Takai, T., Li, M., Sylvestre, D., Clynes, R., & Ravetch, J. V. (1994) · Cell · doi:10.1016/0092-8674(94)90115-5 · Cited by 951
Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 1×
“Approval was based on two phase II studies of DARA monotherapy (16 mg/kg) in heavily treated patients (2, 3).”
MethodApoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Cited by
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M.-V., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., Kaplan, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 988
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028631 · Cited by 702
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G., & Malavasi, F. (2018) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 493
Mateos, M.-V., Cavo, M., Blade, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A., Knop, S., Doyen, C., Lucio, P., Nagy, Z., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 444
Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344
Drug resistance in multiple myeloma
Robak, P., Drozdz, I., Szemraj, J., & Robak, T. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.001 · Cited by 283
Spencer, A., Lentzsch, S., Weisel, K., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194118 · Cited by 263
Bahlis, N. J., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Ho, P. J., Kim, K., Takezako, N., Moreau, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0711-6 · Cited by 238
Casneuf, T., Xu, X. S., Adams, H. C., Axel, A. E., Chiu, C., Khan, I., Ahmadi, T., Yan, X., Lonial, S., Plesner, T., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017006866 · Cited by 229
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
Palladini, G., Kastritis, E., Maurer, M. S., Zonder, J., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Bumma, N., Kaufman, J. L., et al. (2020) · Blood · doi:10.1182/blood.2019004460 · Cited by 211
Dimopoulos, M. A., San-Miguel, J., Belch, A., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kim, K., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.194282 · Cited by 210
Usmani, S. Z., Facon, T. T. F., Hungria, V., Bahlis, N. J., Venner, C. P., Braunstein, M. J., Pour, L., Martí, J. M., Basu, S., Cohen, Y. C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03485-7 · Cited by 206
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Ito, S. (2020) · Cancers · doi:10.3390/cancers12020265 · Cited by 197
Emerging immunotherapies in multiple myeloma
Shah, U. A., & Mailankody, S. (2020) · BMJ · doi:10.1136/bmj.m3176 · Cited by 178
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Martin, T. G., Corzo, K., Chiron, M., van de Velde, H., Abbadessa, G., Campana, F., Solanki, M., Meng, R., Lee, H., Wiederschain, D., et al. (2019) · Cells · doi:10.3390/cells8121522 · Cited by 166
Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Zweegman, S., Caillon, H., Caillot, D., Avet‐Loiseau, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00282-1 · Cited by 164
Adams, H. C., Stevenaert, F., Krejcik, J., Van der Borght, K., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C., Vanhoof, G., et al. (2019) · Cytometry Part A · doi:10.1002/cyto.a.23693 · Cited by 163
Mateos, M.-V., Sonneveld, P., Hungria, V., Nooka, A. K., Estell, J. A., Barreto, W., Corradini, P., Min, C.-K., Medvedova, E., Weisel, K., et al. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.623 · Cited by 160
San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood · doi:10.1182/blood.2020010439 · Cited by 153
Sonneveld, P., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M.-V., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02734 · Cited by 129
Facon, T. T. F., Cook, G., Usmani, S. Z., Hulin, C., Kumar, S. K., Plesner, T., Touzeau, C., Bahlis, N. J., Basu, S., Nahi, H., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01488-8 · Cited by 147
Roussel, M., Merlini, G., Chevret, S., Arnulf, B., Stoppa, A. M., Perrot, A., Palladini, G. O., Karlin, L., Royer, B., Huart, A., et al. (2020) · Blood · doi:10.1182/blood.2019004369 · Cited by 144
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Suzuki, K., Plesner, T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00940 · Cited by 140
Chari, A., Martinez-Lopez, J., Mateos, M.-V., Bladé, J., Benboubker, L., Oriol, A., Arnulf, B., Rodriguez-Otero, P., Pineiro, L., Jakubowiak, A., et al. (2019) · Blood · doi:10.1182/blood.2019000722 · Cited by 136
Wang, Y., Zhang, Y., Hughes, T., Zhang, J., Caligiuri, M. A., Benson, D. M., & Yu, J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3117 · Cited by 124
Casneuf, T., Adams, H., van de Donk, N. W. C. J., Abraham, Y., Bald, J., Vanhoof, G., der Borght, K. V., Smets, T., Foulk, B., Nielsen, K. C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0855-4 · Cited by 130
Landgren, O., Hultcrantz, M., Diamond, B., Lesokhin, A. M., Mailankody, S., Hassoun, H., Tan, C., Shah, U. A., Lu, S. X., Salcedo, M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.0611 · Cited by 119
Immunomodulatory effects of CD38-targeting antibodies
van de Donk, N. W. C. J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.04.005 · Cited by 94
Avet‐Loiseau, H., Miguel, J. F. S., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A. G., Moreau, P., Plesner, T., Weisel, K. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01814 · Cited by 103
Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0718-z · Cited by 102
Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
Domagała, A., Fidyt, K., Bobrowicz, M., Stachura, J., Szczygiel, K., & Firczuk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082256 · Cited by 101
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 101
Anti CD38 monoclonal antibodies for multiple myeloma treatment
Gozzetti, A., Ciofini, S., Simoncelli, M., Santoni, A., Pacelli, P., Raspadori, D., & Bocchia, M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2052658 · Cited by 98
Nooka, A. K., Joseph, N. S., Kaufman, J. L., Heffner, L. T., Gupta, V. A., Gleason, C., Boise, L. H., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32178 · Cited by 91
Cichocki, F. M., Bjordahl, R., Goodridge, J. P., Mahmood, S., Gaidarova, S., Abujarour, R., Davis, Z., Merino, A. M., Tuininga, K., Wang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35127-2 · Cited by 96
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
Sullivan, H. C., Gerner‐Smidt, C., Nooka, A. K., Arthur, C. M., Thompson, L., Mener, A., Patel, S. R., Yee, M. E. M., Fasano, R. M., Josephson, C. D., et al. (2017) · Blood · doi:10.1182/blood-2016-11-749432 · Cited by 94
Ogiya, D., Liu, J., Ohguchi, H., Kurata, K., Samur, M. K., Tai, Y.-T., Adamia, S., Ando, K., Hideshima, T., & Anderson, K. C. (2020) · Blood · doi:10.1182/blood.2019004332 · Cited by 92
Facon, T. T. F., Moreau, P., Weisel, K. C., Goldschmidt, H., Usmani, S. Z., Chari, A., Plesner, T., Orlowski, R. Z., Bahlis, N. J., Basu, S., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02505-2 · Cited by 85
Fan, L., Wang, W., Wang, Z., & Zhao, M. (2021) · Nature Communications · doi:10.1038/s41467-021-26694-x · Cited by 79
Huang, H., Zhu, J., Yao, M., Kim, T. M., Yoon, D. H., Cho, S., Eom, H., Lim, S. T., Yeh, S., Song, Y., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01020-y · Cited by 77
Leleu, X. P., Martin, T. G., Weisel, K. C., Schjesvold, F. H., Iida, S., Malavasi, F., Manier, S., Min, C., Ocio, E. M., Pawlyn, C., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04917-5 · Cited by 77
Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
Chenoweth, A. M., Wines, B. D., Anania, J. C., & Hogarth, P. M. (2020) · Immunology and Cell Biology · doi:10.1111/imcb.12326 · Cited by 76
Bhatla, T., Hogan, L. E., Teachey, D. T., Bautista, F., Moppett, J. P., Velasco, P., Micalizzi, C., Rössig, C., Shukla, N. N., Gilad, G., et al. (2024) · Blood · doi:10.1182/blood.2024024493 · Cited by 75
Chari, A., Rodríguez‐Otero, P., McCarthy, H. O., Suzuki, K., Hungria, V., Sureda, A. M., Perrot, A., Hulin, C., Magen, H., Iida, S., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16980 · Cited by 71
Díaz-Tejedor, A., Lorenzo-Mohamed, M., Puig, N., García‐Sánz, R., Mateos, M., Garayoa, M., & Paíno, T. (2021) · Cancers · doi:10.3390/cancers13061353 · Cited by 70
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
Franssen, L. E., Stege, C. A. M., Zweegman, S., van de Donk, N. W. C. J., & Nijhof, I. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041195 · Cited by 69
Usmani, S. Z., Nahi, H., Legiec, W. M., Grosicki, S., Vorobyev, V. I., Špıčka, I., Hungria, V., Korenkova, S., Bahlis, N. J., Flogegård, M., et al. (2022) · Haematologica · doi:10.3324/haematol.2021.279459 · Cited by 68
Immune Therapies in Multiple Myeloma
Kumar, S. K., & Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0868 · Cited by 68
Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets
Cuesta‐Mateos, C., Alcaraz‐Serna, A., Somovilla-Crespo, B., & Muñoz‐Calleja, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01936 · Cited by 67
McWilliams, E. M., Lucas, C. R., Chen, T. F., Harrington, B. K., Wasmuth, R., Campbell, A. R., Rogers, K. A., Cheney, C. M., Mo, X. M., Andritsos, L. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018025684 · Cited by 67
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 67
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., Grosicki, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.06.005 · Cited by 63
Current developments in immunotherapy in the treatment of multiple myeloma
Köhler, M., Greil, C., Hudecek, M., Lonial, S., Raje, N. S., Wäsch, R., & Engelhardt, M. M. (2018) · Cancer · doi:10.1002/cncr.31243 · Cited by 61
Hulin, C., Offner, F. C., Moreau, P., Roussel, M., Belhadj, K., Benboubker, L., Caillot, D., Facon, T. T. F., Garderet, L., Kuhnowski, F., et al. (2021) · Haematologica · doi:10.3324/haematol.2020.261842 · Cited by 60
Matas‐Céspedes, A., Vidal‐Crespo, A., Rodríguez, V., Villamor, N., Delgado, J., Giné, E., Roca-Ho, H., Menéndez, P. R., Campo, E., López‐Guillermo, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2095 · Cited by 60
Self-citationVogiatzi, F., Winterberg, D., Lenk, L., Buchmann, S., Cario, G., Schrappe, M., Peipp, M., Richter‐Pechańska, P., Kulozik, A. E., Lentes, J., et al. (2019) · Blood · doi:10.1182/blood.2019000904 · Cited by 60
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Dima, D., Dower, J., Comenzo, R. L., & Varga, C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s212526 · Cited by 59
Bisht, K. K., Fukao, T., Chiron, M., Richardson, P. G. G., Atanackovic, D., Chini, E. N., Chng, W. J., de Velde, H. J. V., & Malavasi, F. (2023) · Cancer Medicine · doi:10.1002/cam4.6619 · Cited by 57
Mateos, M., Spencer, A. G., Nooka, A. K., Pour, L., Weisel, K. C., Cavo, M., Laubach, J. P., Cook, G., Iida, S., Benboubker, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.217448 · Cited by 57
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksaç, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A. S., Bila, J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00218-1 · Cited by 56
Gauthier, M., Laroye, C., Bensoussan, D., Boura, C., & Decot, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103261 · Cited by 56
Vidal‐Crespo, A., Matas‐Céspedes, A., Rodríguez, V., Rossi, C., Valero, J. G., Serrat, N., Sanjuán-Pla, A., Menéndez, P. R., Roué, G., López‐Guillermo, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.211904 · Cited by 53
Daratumumab for the treatment of multiple myeloma
Touzeau, C., & Moreau, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1322578 · Cited by 52
Leblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 52
An update on the biologics for the treatment of antiphospholipid syndrome
Yun, Z., Duan, L., Liu, X., Cai, Q., & Li, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145145 · Cited by 52
Nabar, N. R., Heijjer, C. N., Shi, C.-S., Hwang, I., Ganesan, S., Karlsson, M. C. I., & Kehrl, J. H. (2021) · Autophagy · doi:10.1080/15548627.2021.1954779 · Cited by 51
ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab
Kang, L., Jiang, D., England, C. G., Barnhart, T. E., Yu, B., Rosenkrans, Z. T., Wang, R., Engle, J. W., Xu, X., Huang, P., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3941-3 · Cited by 51
Perrot, A., Facon, T. T. F., Plesner, T., Usmani, S. Z., Kumar, S. K., Bahlis, N. J., Hulin, C., Orlowski, R. Z., Nahi, H., Mollee, P. N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01370 · Cited by 50
Daratumumab in untreated newly diagnosed multiple myeloma
Abdallah, N. H., & Kumar, S. K. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719894871 · Cited by 49
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Soto, J. A. M., Broekmans, M. E. C., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C. A. M., et al. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1443809 · Cited by 48
Self-citationBiorecognition: A key to drug-free macromolecular therapeutics
Yang, J., Li, L., & Kopec̆ek, J. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.007 · Cited by 48
Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
Kinder, M., Bahlis, N. J., Malavasi, F., de Goeij, B. E. C. G., Babich, A., Sendecki, J. A., Rusbuldt, J. J., Bellew, K. M., Kane, C. M., & van de Donk, N. W. C. J. (2021) · Haematologica · doi:10.3324/haematol.2020.268656 · Cited by 46
Quach, H., Benson, S., Haysom, H. E., Wilkes, A., Zacher, N., Cole-Sinclair, M. F., Prince, H. M., Mollee, P. N., Spencer, A. G., Ho, P. J., et al. (2018) · Internal Medicine Journal · doi:10.1111/imj.13707 · Cited by 44
Callander, N. S., Silbermann, R. W., Kaufman, J. L., Godby, K. N., Laubach, J. P., Schmidt, T. M., Sborov, D. W., Medvedova, E., Reeves, B., Dhakal, B., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01030-w · Cited by 43
Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia
Manna, A., Aulakh, S., Jani, P., Ahmed, S., Akhtar, S., Coignet, M. V., Heckman, M. G., Meghji, Z., Bhatia, K., Sharma, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3412 · Cited by 43
Calabretta, E., & Carlo‐Stella, C. (2020) · Cells · doi:10.3390/cells9040802 · Cited by 43
Weisel, K. C., Spencer, A. G., Lentzsch, S., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00948-5 · Cited by 43
Salles, G. A., Gopal, A. K., Minnema, M. C., Wakamiya, K., Feng, H., Schecter, J. M., & Wang, M. L. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.013 · Cited by 43
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Blair, H. A. (2017) · Drugs · doi:10.1007/s40265-017-0837-7 · Cited by 42
Miguel, J. F. S., Usmani, S. Z., Mateos, M., van de Donk, N. W. C. J., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Liu, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.243790 · Cited by 42
Isatuximab for the treatment of relapsed/refractory multiple myeloma
Richardson, P. G. G., Beksaç, M., Špıčka, I., & Mikhael, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1841747 · Cited by 41
Lu, J., Fu, W., Li, W., Hu, J., An, G., Wang, Y., Fu, C., Chen, L., Jin, J., Cen, X., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.04.012 · Cited by 41
Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab
Kim, K., & Phelps, M. A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01240-8 · Cited by 40
Chari, A., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Silbermann, R. W., Costa, L. J., Anderson, L. D., Nathwani, N., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01088-6 · Cited by 40
Mills, J. R., & Murray, D. L. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.020784 · Cited by 39
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Choi, A. Y., Manook, M., Olaso, D., Ezekian, B., Park, J. B., Freischlag, K., Jackson, A. M., Knechtle, S. J., & Kwun, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.694763 · Cited by 39
Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
Al‐Odat, O. S., Guirguis, D. A., Schmalbach, N. K., Yao, G., Budak-Alpdoǧan, T., Jonnalagadda, S. C., & Pandey, M. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010644 · Cited by 39
CD38 as theranostic target in oncology
Bocuzzi, V., Bridoux, J., Pirotte, M., Withofs, N., Hustinx, R., D’Huyvetter, M., Caers, J., & Marcion, G. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05768-6 · Cited by 38
Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
Sherbenou, D. W., Mark, T. M., & Forsberg, P. A. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.030 · Cited by 38
Mateos, M., Miguel, J. F. S., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Pour, L., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00018-x · Cited by 37
Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets
Vaisitti, T., Arruga, F., Guerra, G., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02301 · Cited by 37
Usmani, S. Z., Diels, J., Ito, T., Mehra, M., Khan, I., & Lam, A. (2017) · American Journal of Hematology · doi:10.1002/ajh.24781 · Cited by 37
Metadata
- Authors
- Overdijk, M. B., Jansen, J. H. M., Nederend, M., Lammerts van Bueren, J. J., Groen, R. W. J., Parren, P. W. H. I., Leusen, J. H. W., & Boross, P.
- Affiliations
- Genmab (Netherlands) (NL)
- University Medical Center Utrecht (NL)
- Genmab , 3584 CM Utrecht,
- University of Southern Denmark (DK)
- Immunotherapy Laboratory, Laboratory for Translational Immunology, University Medical Center , 3584 CX Utrecht,
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-08-01
- Volume
- 197
- Issue
- 3
- Pages
- 807-813
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2443548094
- Cited by
- 297
- References
- 51
- Citations by year
- 2026: 17 · 2025: 22 · 2024: 21 · 2023: 27 · 2022: 35 · 2021: 45 · 2020: 44 · 2019: 34 · 2018: 27 · 2017: 19 · 2016: 4
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- The Journal of Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- daratumumab, anti-CD38 monoclonal antibody, programmed cell death, multiple myeloma, FcRγ chain, FcγRIIB, FcγRIII, antibody-dependent cellular cytotoxicity
- MeSH terms
- Animals, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Disease Models, Animal, Humans, Mice, Inbred C57BL, Multiple Myeloma, Tumor Cells, Cultured, Apoptosis, Receptors, IgG, Mice, Knockout, Mice, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.